Johnson & Johnson Stops Mid-Stage Eczema Drug Trial
TL;DR Summary
Johnson & Johnson has discontinued its mid-stage trial of the experimental eczema drug JNJ-5939 after it failed to meet efficacy goals, but remains committed to developing other treatments for atopic dermatitis.
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
1 min
vs 1 min read
Condensed
81%
166 → 31 words
Want the full story? Read the original article
Read on CNBC